NCT04352595View on ClinicalTrials.gov

A Phase Ⅱ Study of Hemay808 for Atopic Dermatitis Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

148

Participants

Timeline

Start Date

April 24, 2020

Primary Completion Date

February 28, 2021

Study Completion Date

April 2, 2021

Conditions
Atopic Dermatitis
Interventions
DRUG

Hemay808

Hemay808 is a onitment of Hemay028, a small molecule PDE4 inhibitor.

Trial Locations (2)

210042

Dermotology hospital, Chinese academy of medical science, Nanjing

315010

Ningbo second hospital, Ningbo

All Listed Sponsors
lead

Tianjin Hemay Pharmaceutical Co., Ltd

INDUSTRY

NCT04352595 - A Phase Ⅱ Study of Hemay808 for Atopic Dermatitis Patients | Biotech Hunter | Biotech Hunter